<DOC>
	<DOCNO>NCT01691339</DOCNO>
	<brief_summary>The aim study evaluate safety immunogenicity Fluzone vaccine ( 18 year &lt; 65 year age ≥ 65 year age ) , Fluzone Intradermal vaccine ( 18 year &lt; 65 year age ) , Fluzone High-Dose vaccine ( ≥ 65 year age ) . Primary Objective : - To describe safety 2012 - 2013 formulation Fluzone Fluzone Intradermal vaccine adult 18 &lt; 65 year age safety 2012 - 2013 formulation Fluzone Fluzone High-Dose vaccine adult ≥ 65 year age . Observational Objectives : - To describe immunogenicity 2012 - 2013 formulation Fluzone Fluzone Intradermal vaccine adult 18 &lt; 65 year age immunogenicity 2012 - 2013 formulation Fluzone Fluzone High-Dose vaccine adult ≥ 65 year age . - To evaluate compliance , term immunogenicity , study vaccine ( Fluzone , Fluzone Intradermal , Fluzone High-Dose ) applicable age group requirement Committee Human Medicinal Products ( CHMP ) Note Guidance ( NfG ) CPMP/BWP/214/96 . - To submit remain available serum subject give Fluzone vaccine Center Biologics Evaluation Research ( CBER ) analysis World Health Organization ( WHO ) , Centers Disease Control Prevention ( CDC ) , Food Drug Administration ( FDA ) support selection recommendation strain subsequent year ' influenza vaccine .</brief_summary>
	<brief_title>Study Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults .</brief_title>
	<detailed_description>Participants 18 &lt; 65 year age randomize receive dose either Fluzone Fluzone Intradermal vaccine participant ≥ 65 year age randomize receive dose Fluzone Fluzone High-Dose vaccine . All participant follow safety immunogenicity . The duration participation trial approximately 21 day .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject ≥ 18 year age day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure . History serious adverse reaction influenza vaccine Receipt vaccine within 30 day receive study vaccine , plan receive another vaccine Visit 2 Participation another interventional clinical trial investigate vaccine , drug , medical device , medical procedure 30 day precede first study vaccination course study , unless intervention study occur within 30 day prior first study vaccination none plan subject would complete safety surveillance present study Thrombocytopenia , may contraindication intramuscular vaccination , discretion Investigator Prior vaccination 2012 2013 formulation influenza vaccine Known systemic hypersensitivity egg , chicken protein , latex , vaccine component , history lifethreatening reaction Fluzone , Fluzone Intradermal , Fluzone HighDose vaccine vaccine contain substance ( complete list vaccine component include Prescribing Information ) Receipt immune globulin , blood , bloodderived product past 3 month Bleeding disorder receipt anticoagulants 3 week precede inclusion , may contraindication intramuscular vaccination , discretion Investigator Subject pregnant , lactating , childbearing potential ( consider nonchildbearing potential , female must premenarche postmenopausal least 1 year , surgically sterile , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination ) Any condition opinion Investigator would pose health risk subject enrol could interfere evaluation vaccine Personal history GuillainBarré syndrome Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Chronic illness , opinion Investigator , stage might interfere trial conduct completion Seropositivity human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C , report subject Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol drug addiction , opinion Investigator , might interfere ability comply trial procedure Moderate severe acute illness/infection ( accord Investigator judgment ) febrile illness ( temperature ≥ 100.4°F ) day vaccination . A prospective subject include study condition resolve febrile event subside Identified Investigator employee Investigator study center direct involvement propose study , identify immediate family member ( i.e. , parent , spouse , natural adopt child ) Investigator employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza virus vaccine</keyword>
	<keyword>Fluzone® ( Influenza Virus Vaccine ) 2012-2013 Formulation</keyword>
	<keyword>Fluzone® High-Dose ( Influenza Virus Vaccine ) 2012-2013 Formulation</keyword>
	<keyword>Trivalent Inactivated Influenza Vaccine</keyword>
	<keyword>Fluzone® Intradermal ( Influenza Virus Vaccine ) 2012-2013 Formulation</keyword>
</DOC>